Viyash Scientific Share Price Today

Viyash Scientific completes acquisition of BioForLife Italia

Viyash Scientific's subsidiary Alivira Animal Health acquired 100% of BioForLife Italia S.r.l. Base purchase consideration paid on closing is EUR 15.0 million. Deferred consideration of EUR 1.976 million payable subject to adjustments. Acquisition completed on October 1, 2026, making BFL Italy a step-down subsidiary.

Viyash Scientific secures Italian regulatory approval for BioForLife acquisition

Viyash Scientific received Italian FDI/Golden Power regulatory approval for acquiring BioForLife Italia S.r.l. The 100% stake acquisition is being executed by Irish subsidiary Alivira Animal Health Limited. Completion of the transaction is now expected within two months from September 8, 2026. All other material terms from earlier disclosures in June and July 2026 remain unchanged.

Viyash Scientific promoters sell 50.3M shares in open market

Promoters CA Harbor and CA Hull sold 5,03,65,847 Viyash Scientific shares on August 26, 2026. CA Harbor reduced stake from 30.14% to 24.47%; CA Hull from 31.17% to 25.31%. Transactions were executed in the open market without any pledged shares involved. Combined promoter holding in diluted capital falls to 45.31% post-sale.

Viyash Scientific profit doubles in Q1FY27; eyes Italy deal

Viyash Scientific posted a 115% surge in Q1FY27 net profit to ₹793 million, driven by 19.5% revenue growth and significant margin expansion. Consolidated EBITDA rose 59.2% to ₹2,047 million, with margins expanding to 21.6%. The company reduced net debt to ₹861 million, achieving a 0.1x net debt-to-EBITDA ratio. Strategic initiatives include the pending acquisition of Bio For Life in Italy and continued growth in US and emerging markets.

Viyash Scientific passes key resolutions at 41st AGM

Viyash Scientific Limited held its 41st AGM on August 11, 2026, via video conference. Shareholders approved the FY26 financial statements, re-appointed Dr. Haribabu Bodepudi and Mr. Rajaram Narayanan as directors, and ratified Cost Auditor remuneration for FY25-2026 and FY26-2027. A special resolution for new Articles of Association was also tabled. The meeting adhered to MCA and SEBI guidelines, with clear communication on voting procedures and document accessibility.

Viyash Scientific Q1FY26 net profit surges 115% as EBITDA margin expands

Viyash Scientific's Q1FY26 net profit surged 115% to ₹792.90 million as revenue grew 19.5% to ₹9,463.60 million. EBITDA margin expanded to 18.9%. The Board approved ESOP allotments, a Vietnam subsidiary, and loan-to-equity conversion for AAHL.